3 min read

Are You Ready For Sentinel? | New RWE Safety Initiative

Continued funding shows the FDA’s commitment to RWE in product safety.
With continued investment in the RWE space, find out how to meet the needs of regulators, payers, and prescribers.

FDA Continues to Support the Sentinel Initiative

An October 1 announcement of FDA’s funding of $220 Million to the Harvard Pilgrim Health Care Institute for the next phase of FDA’s Sentinel System brings continued focus on FDA’s commitment to evaluating Real World Evidence (RWE) for informing prescribers and patients about product safety. Key to the Sentinel System is a network of electronic medical records that can be utilized rapidly to address issues of concern.

UBC has been at the forefront of the RWE arena for the past 15 years and has developed methodological depth as well as automated tools that generate rapid insights from real world claims and EMR databases. The key to validated, automated evaluation and response is our SᴁfetyWorks® tool that allows for analysis without programming. Our comprehensive solution includes:

  • Global Database Feasibility Studies
    •   In-depth review of data elements and literature
    • Understanding data strengths and limitations
    •  Direct discussions with data vendors
    • Data agnostic – recommendations based on database ‘fit for purpose’
  • Protocol Development – Designing Post-Marketing Safety Studies
    •  Cumulatively, over 100 years of experience developing the appropriate study design to provide meaningful results
    • Proven track record of developing protocols accepted by the EMA and FDA
  • Study Implementation
    • Customized studies and/or automated analytics according to the approved study protocol
    • Established relationships with US and European data vendors
    • Use of formal SOPs for study conduct and validation of results
  • RWD automated software for signal identification and refinement
    • SÆfetyWorks® analytics software leverages RWD for performing signal refinement and evaluation to supplement signal identification based on spontaneous case reports.
    • Aligned with FDA’s Sentinel Initiative methods of signal identification and evaluation.

Take steps now to partner with a patient-support services company with extensive RWE safety experience including in signal detection and analyses. Contact UBC to see if you are positioned for Sentinel and to learn more.

Other Recent Posts

3 min read

UBC Appoints Anthony Luttenberger Chief Commercial Officer

Biopharma services industry veteran brings decades of experience spanning late-stage, clinical trials, & post-approval commercial support.
1 min read

UBC Listed as a Citeline Awards Finalist for Excellence in RWE

UBC is once again a finalist for the Citeline Awards, with our 2024 nomination coming in the Excellence in RWE category.
3 min read

UBC Recognized as a Citeline Awards Finalist Again

The Citeline Awards have recognized UBC & Seqster’s innovative collaboration as a shortlisted finalist for the Best Patient-Facing Technology Initiative Category in 2023.

Thank You for Connecting with UBC

Lorem ipsum dolor sit amet consectetur. Mi proin enim ipsum nascetur. Venenatis odio scelerisque non netus ac et pellentesque.

What You Can Expect Next

Lorem ipsum dolor sit amet consectetur. Cras aliquam erat eget magna sollicitudin.

Get Ready to Change Your Business

Lorem ipsum dolor sit amet consectetur. Mi proin enim ipsum nascetur. Venenatis odio scelerisque non netus ac et pellentesque.

Service Request

Bekki Bracken Brown

President & Chief Executive Officer

Bekki Bracken Brown serves as the President and CEO of UBC, guiding the company’s mission and values, including the improvement of access for patients to receive better outcomes. She oversees all aspects of UBC, such as operations, business growth strategy, sales and marketing, and acquisition support.

With over 20 years of industry experience, Ms. Brown brings knowledge from a successful career in senior management from her tenure at Quintiles, INC Research, and, most recently, with Syneos Health. She’s been a member of the North Carolina BIO Board of Directors since 2019. She is also a member of the Healthcare Businesswomen’s Association — Southeast Chapter and CHIEF, an organization that supports women executive leaders. Ms. Brown earned her bachelor’s degree at Duke University.